Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.7K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.7K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

2.7K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
2.7K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.6K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of Middle Hepatic Vein Tributaries Preserving Technique Until Just Before Graft Retrieval on Donors' Surgical Outcomes in Living Donor Liver Transplantation.

Transplantation proceedings·2018
Same author

A Case of Successful Simultaneous Pancreas-Kidney Transplantation Using the Injured Pancreas Graft.

Transplantation proceedings·2017
Same author

Influence of ions on two-dimensional and three-dimensional atomic force microscopy at fluorite-water interfaces.

Nanotechnology·2017
Same author

Leaf nitrogen distribution in relation to leaf age and photon flux density in dominant and subordinate plants in dense stands of a dicotyledonous herb.

Oecologia·2017
Same author

Resveratrol Prevents Warm Ischemia-Reperfusion Injury in Liver Grafts From Non-Heart-Beating Donor Rats.

Transplantation proceedings·2016
Same author

STAT3 integrates cooperative Ras and TGF-β signals that induce Snail expression.

Oncogene·2015

Related Experiment Video

Updated: Apr 29, 2026

Studying Orthodontic Tooth Movement in Mice
07:17

Studying Orthodontic Tooth Movement in Mice

Published on: August 2, 2024

1.7K

Selective β2-adrenergic Antagonist Butoxamine Reduces Orthodontic Tooth Movement.

T Sato1, K Miyazawa2, Y Suzuki2

  • 1Department of Orthodontics, School of Dentistry, Aichi-Gakuin University, Nagoya, Japan tk-mail@dpc.agu.ac.jp.

Journal of Dental Research
|May 29, 2014
PubMed
Summary
This summary is machine-generated.

Butoxamine (BUT), a beta-2 adrenergic receptor (β2-AR) antagonist, was studied for its effects on bone metabolism and tooth movement. BUT treatment in spontaneously hypertensive rats reduced alveolar bone loss and orthodontic tooth movement by blocking β2-AR.

Keywords:
bone remodelingorthodonticsosteoclastosteoporosisperiodontal disease/periodontitissympathetic nervous system

More Related Videos

Author Spotlight: Insights into an Efficient Murine Maxillary Orthodontic Model Protocol
04:11

Author Spotlight: Insights into an Efficient Murine Maxillary Orthodontic Model Protocol

Published on: October 27, 2023

1.5K
Author Spotlight: Comparing Alveolar and Long Bone Remodeling to Explore OTM Model Potential
05:25

Author Spotlight: Comparing Alveolar and Long Bone Remodeling to Explore OTM Model Potential

Published on: July 21, 2023

2.0K

Related Experiment Videos

Last Updated: Apr 29, 2026

Studying Orthodontic Tooth Movement in Mice
07:17

Studying Orthodontic Tooth Movement in Mice

Published on: August 2, 2024

1.7K
Author Spotlight: Insights into an Efficient Murine Maxillary Orthodontic Model Protocol
04:11

Author Spotlight: Insights into an Efficient Murine Maxillary Orthodontic Model Protocol

Published on: October 27, 2023

1.5K
Author Spotlight: Comparing Alveolar and Long Bone Remodeling to Explore OTM Model Potential
05:25

Author Spotlight: Comparing Alveolar and Long Bone Remodeling to Explore OTM Model Potential

Published on: July 21, 2023

2.0K

Area of Science:

  • Bone Biology and Physiology
  • Endocrinology and Metabolism
  • Dental and Craniofacial Research

Background:

  • The sympathetic nervous system plays a role in bone metabolism.
  • Beta-2 adrenergic receptors (β2-AR) are present on bone cells.
  • Previous research indicated low-dose beta-AR blockers improve osteoporosis, while high doses may inhibit osteoblastic activity.

Purpose of the Study:

  • To investigate the effects of butoxamine (BUT), a selective β2-AR antagonist, on tooth movement and alveolar bone metabolism in spontaneously hypertensive rats (SHR).
  • To explore the potential of β2-AR blockade in managing bone loss associated with sympathetic nervous system hyperactivity.

Main Methods:

  • Administration of BUT (1 mg/kg) orally to spontaneously hypertensive rats (SHR).
  • Insertion of closed-coil springs to induce orthodontic tooth movement in the upper-left first molar.
  • Analysis of tooth movement distance, alveolar bone microarchitecture, and histomorphometry post-treatment.
  • Assessment of tyrosine hydroxylase (TH)-immunoreactive nerves in the periodontal ligament.

Main Results:

  • SHR exhibited greater tooth movement and alveolar bone loss (increased bone resorption) compared to Wistar-Kyoto rats.
  • BUT treatment significantly reduced tooth movement in SHR, bringing it to levels comparable to controls.
  • BUT administration led to a recovery of alveolar bone loss in SHR.
  • BUT treatment decreased the number of TH-immunoreactive nerves in the periodontal ligament.

Conclusions:

  • Butoxamine (BUT) effectively prevents alveolar bone loss in spontaneously hypertensive rats.
  • BUT administration inhibits orthodontic tooth movement, likely through β2-adrenergic receptor (β2-AR) blockade.
  • These findings suggest a therapeutic potential for β2-AR antagonists in conditions involving bone loss and sympathetic hyperactivity.